Merck Unsure Whether Vytorin, Zetia Can Cushion Fosamax’s Patent Loss

Sales of Merck's new and inline products will drive growth in 2008 as the company turns to drugs like Januvia, Singulair, Cozaar/Hyzaar and vaccines to cushion the blow from the loss of exclusivity for Fosamax, Chief Financial Officer Peter Kellogg reported during the company's year-end financial call Jan. 30